Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine

Jerald J. Killion, Corazon D. Bucana, Robert Radinsky, Zhongyun Dong, Terry O'Reilly, Graham Bilbe, Lajos Tarcsay, Isaiah J. Fidler

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

The systemic administration of doxorubicin (DXR) decreases the number of epithelial cells and leukocytes in the small intestine of mice. Oral administration of muramyl tripeptide phosphatidylethanolamine (MTP-PE) prevented both disruption of intestinal architecture, and a decrease in the number of macrophages, and it induced the expression of IL-6, G-CSF, GM-CSF, and TNF-α in the intestinal tissue. The data suggest that the oral administration of MTP-PE can prevent chemotherapy-induced toxicity to the intestinal mucosa and hence infections due to translocation of aerobic bacteria from the intestine to the blood.

Original languageEnglish (US)
Pages (from-to)363-371
Number of pages9
JournalCancer Biotherapy and Radiopharmaceuticals
Volume11
Issue number6
DOIs
StatePublished - Dec 1996

Keywords

  • MTP-PE
  • chemotherapy
  • intestinal epithelium

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine'. Together they form a unique fingerprint.

Cite this